Multiple Endocrine Neoplasia Type 2a
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher expression of miR-885-5p and miR-1225-3p was found in multiple endocrine neoplasia type 2 and sporadic recurring pheochromocytomas, respectively.
|
20818339 |
2010 |
Multiple endocrine neoplasia Type 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher expression of miR-885-5p and miR-1225-3p was found in multiple endocrine neoplasia type 2 and sporadic recurring pheochromocytomas, respectively.
|
20818339 |
2010 |
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.
|
22071691 |
2011 |
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Taken together, these data provide evidence that miR-885-5p has a tumor suppressive role in neuroblastoma interfering with cell cycle progression and cell survival.
|
21233845 |
2011 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data provide evidence that miR-885-5p has a tumor suppressive role in neuroblastoma interfering with cell cycle progression and cell survival.
|
21233845 |
2011 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data provide evidence that miR-885-5p has a tumor suppressive role in neuroblastoma interfering with cell cycle progression and cell survival.
|
21233845 |
2011 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data provide evidence that miR-885-5p has a tumor suppressive role in neuroblastoma interfering with cell cycle progression and cell survival.
|
21233845 |
2011 |
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MiR-885-5p is highly up-regulated in oncocytic follicular carcinomas and may serve as a diagnostic marker for these tumors.
|
23150679 |
2013 |
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer.
|
23271051 |
2013 |
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Novel miRNA (miR-885-5p) was found to be strongly up-regulated (>40-fold) in oFTCs but not in cFTCs, follicular adenomas, and HNs.
|
23150679 |
2013 |
Follicular thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The classification and regression tree algorithm applied to fine-needle aspiration samples demonstrated that three dysregulated miRNAs (miR-885-5p/-221/-574-3p) allowed distinguishing follicular thyroid carcinomas from benign HNs with high accuracy.
|
23150679 |
2013 |
Malignant Head and Neck Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer.
|
23271051 |
2013 |
Squamous cell carcinoma of the head and neck
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our data suggest that the miR-885-5p binding site rs1049253T>C SNP in the 3'-UTR of CASP3 modulates CASP3 expression at both mRNA and protein levels and thus contributes to SCCHN susceptibility.
|
23271051 |
2013 |
Head and Neck Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer.
|
23271051 |
2013 |
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In conclusion, our findings suggest that miR-885-5p and CIMP status may be useful biomarkers for predicting biological malignancy in patients with rectal carcinoid tumors.
|
26090613 |
2015 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, our findings suggest that miR-885-5p and CIMP status may be useful biomarkers for predicting biological malignancy in patients with rectal carcinoid tumors.
|
26090613 |
2015 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, high miR-885-5p expression was independently associated with lymphovascular invasion (P = 0.0002).
|
26090613 |
2015 |
Carcinoid Tumor
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The array analysis revealed that microRNA-885 (miR-885)-5p was the most up-regulated miRNA in the carcinoid tumors with lymphovascular invasion compared with that in those without invasion.
|
26090613 |
2015 |
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
|
24882581 |
2015 |
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
|
24882581 |
2015 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, our findings suggest that miR-885-5p and CIMP status may be useful biomarkers for predicting biological malignancy in patients with rectal carcinoid tumors.
|
26090613 |
2015 |
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results support a novel role for miR-885-3p in tumor angiogenesis by targeting BMPR1A, which regulates a proangiogenic factor, and provide new evidence that targeting miRNAs might be an effective therapeutic strategy for improving colon cancer treatment.
|
24882581 |
2015 |
Neoplasm Metastasis
|
0.330 |
Therapeutic
|
phenotype |
CTD_human |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
Neoplasm Metastasis
|
0.330 |
Biomarker
|
phenotype |
BEFREE |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy (AUC = 1) for early detection of HCC in normal population while using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy (AUC = 0.982) for early detection of HCC in LC patients.
|
27271989 |
2016 |